Literature DB >> 32338735

Fulminant myocarditis in the time of coronavirus.

Vittoria Cuomo1, Roberta Esposito1, Ciro Santoro1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32338735      PMCID: PMC7197560          DOI: 10.1093/eurheartj/ehaa354

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
This Commentary refers to: ‘Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin’, by H. Hu . We congratulate Hongde Hu et al. for their timely work concerning a case of healed fulminant myocarditis. The authors suggest that the diagnosis is coronavirus myocarditis because nucleic acid tests for 11 other viruses were negative. Although very likely, the diagnosis is not certain. Not all the diagnostic tests necessary for a differential diagnosis have been carried out. Global type stress-induced cardiomyopathy has not been ruled out with certainty. The authors state that glucocorticoid and immunoglobulin therapy are of important value in this type of patient and conclude that this case report is helpful in treating other similar patients. We disagree with these conclusions. Early glucocorticoid therapy has not been proven with certainty to be effective in acute myocarditis. In a systematic review including 719 patients, corticosteroids did not reduce mortality. Glucocorticoids exacerbate acute murine viral myocarditis. The current position statement of the European Society of Cardiology recommends that immunosuppression should be started only after ruling out active infection. The patient presented in the case report had an acute infection. Moreover, limited data are available on the use of immunoglobulins in acute myocarditis. A systematic review of intravenous immunoglobulins for therapy of acute myocarditis concluded that there are insufficient data to recommend their routine use. In the absence of multicentre randomized studies, the European Society of Cardiology does not give recommendations for the use of immunoglobulins in acute myocarditis. It is possible that further studies may identify a subset of patients with acute coronavirus myocarditis responsive to such a regimen of glucocorticoid and human immunoglobulin. Until then, current literature data do not seem to justify the extensive use of these therapies. Conflict of interest: none declared.
  5 in total

Review 1.  Ex uno, plures-From One Tissue to Many Cells: A Review of Single-Cell Transcriptomics in Cardiovascular Biology.

Authors:  Elvira Forte; Micheal A McLellan; Daniel A Skelly; Nadia A Rosenthal
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

Review 2.  Clinical variants of myocardial involvement in COVID-19-positive patients: a cumulative experience of 2020.

Authors:  Maya Guglin; Kareem Ballut; Onyedika Ilonze; Mark Jones; Roopa Rao
Journal:  Heart Fail Rev       Date:  2021-07-02       Impact factor: 4.654

3.  The saga continues: is COVID-19 a cardiopulmonary disease?

Authors:  Thomas F Lüscher
Journal:  Eur Heart J       Date:  2020-06-07       Impact factor: 29.983

4.  COVID-19: (mis)managing an announced Black Swan.

Authors:  Thomas F Lüscher
Journal:  Eur Heart J       Date:  2020-05-14       Impact factor: 29.983

Review 5.  Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection.

Authors:  Radha Gopal; Michael A Marinelli; John F Alcorn
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.